Novo Nordisk A/S

NVO · OMX

$39.05−$0.38 (−0.96%)TodayMarket closed · Oct 23, 7:59 PM ET

Prev close $39.43

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Employees: 68,794
Headquarters: Bagsvaerd
Listed: May 17, 1974
Sector: Health Care
Industry: Pharmaceuticals
Website: novonordisk.com

Leadership

Novo Nordisk A/S executives
Name	Title	Since	Age
Helge Lund	—	—	62
Maziar Doustdar	—	—	54
Henrik Poulsen	—	2021	57
Karsten Munk Knudsen	—	—	53
Martin Lange	—	—	54
Thilde Bogebjerg	—	—	—
Ludovic Helfgott	—	—	50
Emil Larsen	—	—	—
David Moore	—	—	51
Tania Sabroe	—	—	47
Henrik Wulff	—	—	54
Mette Boejer Jensen	—	—	49
Elisabeth Christensen	—	—	59
Liselotte Hyveled	—	—	59
Kasim Kutay	—	—	59
Thomas Rantzau	—	—	52
Laurence Debroux	—	—	55
Andreas Fibig	—	—	63
Sylvie Gregoire	—	—	63
Christina Law	—	—	58
Martin Mackay	—	—	69
Jacob Rode	—	2024	—

Revenue by product and region

Fiscal year ended Dec 31, 2024: $290.40B total revenue

By product

Diabetes and Obesity care$271.76B93.6%
Rare disease$18.64B6.4%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.